Replies to post #108089 on Biotech Values

[DewDiligence]

By your logic, Amphastar too must have modified its original formulation because the two ANDA’s have been under review for the same amount of time and neither has been formally rejected. HSP’s Lovenox ANDA for the vial formulation has not been rejected either. Something for you to think about…

[DewDiligence]

I've been circumspect to this point, but now I'm just going to come out and say I think your source is full of crap…

Do you also think the Wall Street Journal is full of crap for reporting that Teva’s Lovenox application is “stuck in bureaucratic limbo”?